Government Briefs

The Incredible Shrinking Tax Credit Congress has once again retained tax credits to companies both for their in-house R&D and for contributions to basic research at universities and other nonprofit research institutions. But the credit is steadily shrinking. The original law for new R&D spending was a 25% credit for four years. In 1986 the credit was extended for two years and lowered to 20%, and in 1988 one more year was added. The basic research credit, created in 1986, has followed a similar


Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The Incredible Shrinking Tax Credit Congress has once again retained tax credits to companies both for their in-house R&D and for contributions to basic research at universities and other nonprofit research institutions. But the credit is steadily shrinking. The original law for new R&D spending was a 25% credit for four years. In 1986 the credit was extended for two years and lowered to 20%, and in 1988 one more year was added. The basic research credit, created in 1986, has followed a similar path. This year Congress approved what amounts to a nine-month extension, after revising a bill passed by the House of Representatives and the Senate Finance Committee that contained a permanent credit. "We came within a hair's breadth of getting it all," says Kenneth Kay, executive director of CORETECH, an industry-university consortium that has lobbied hard for the credit. "It's disheartening, but it's better than a December ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide